Key Highlights
- EyePoint Pharmaceuticals' Phase 3 LUGANO trial for DURAVYU missed the primary BCVA endpoint in the full dataset.
- Ad hoc exclusion of 9 unrelated vision-loss patients showed non-inferiority to aflibercept.
- Secondary endpoints demonstrated 42% lower treatment burden and strong supplement-free rates.
- Approval prospects now depend on Q4 2026 LUCIA data and a planned H1 2027 NDA.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) reported that its Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration missed the primary best-corrected visual acuity endpoint in the full dataset.
What Happened
Ad hoc exclusion of 9 unrelated vision-loss patients showed non-inferiority to aflibercept, and secondary endpoints demonstrated 42% lower treatment burden, strong supplement-free rates, and a favorable safety profile.
Approval prospects are now dependent on Q4 2026 LUCIA data and a planned NDA submission in the first half of 2027.
Market Reaction
The disclosed information does not include stock price or trading data for EyePoint Pharmaceuticals following the trial results.
Outlook
Q4 2026 LUCIA data represents the next major disclosed milestone for DURAVYU in wet AMD, ahead of the company's planned NDA submission in the first half of 2027.
FAQs
Q: Did EyePoint's Phase 3 LUGANO trial meet its primary endpoint?
A: No, the trial missed the primary BCVA endpoint in the full dataset, though an ad hoc analysis excluding 9 unrelated vision-loss patients showed non-inferiority to aflibercept.
Q: What did the secondary endpoints show?
A: A 42% lower treatment burden, strong supplement-free rates, and a favorable safety profile.
Q: What is the path forward for DURAVYU's approval?
A: It depends on Q4 2026 LUCIA data and a planned NDA submission in the first half of 2027.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.